FdaApplication
BLA 761345
Identifiers
- fda_app_no: BLA761345
Properties
| Property | Value |
|---|---|
| applicant_name | Pfizer Inc. |
| application_type | BLA |
| approval_date | 2023-08-14 |
Revenue by product
ELREXFIO
| Period | Revenue |
|---|---|
| Q2 2026 | $89.0M |
| Q1 2026 | $80.0M |
| Q3 2025 | $85.0M |
| Q2 2025 | $85.0M |
| Q1 2025 | $60.0M |
| Q3 2024 | $40.0M |
| Q2 2024 | $22.0M |
| Q1 2024 | $13.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
ELREXFIO
| Period | Revenue |
|---|---|
| Q2 2026 | $89.0M |
| Q1 2026 | $80.0M |
| Q3 2025 | $85.0M |
| Q2 2025 | $85.0M |
| Q1 2025 | $60.0M |
| Q3 2024 | $40.0M |
| Q2 2024 | $22.0M |
| Q1 2024 | $13.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ELREXFIO | ELRANATAMAB | 76MG/1.9ML (40MG/ML) | Injection |
| ELREXFIO | — | 44MG/1.1ML (40MG/ML) | Injection |
2 products